5 results on '"Hudis, Clifford A."'
Search Results
2. Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas.
- Author
-
Kunitake, Jennie A.M.R., Choi, Siyoung, Nguyen, Kayla X., Lee, Meredith M., He, Frank, Sudilovsky, Daniel, Morris, Patrick G., Jochelson, Maxine S., Hudis, Clifford A., Muller, David A., Fratzl, Peter, Fischbach, Claudia, Masic, Admir, and Estroff, Lara A.
- Subjects
- *
CALCIFICATIONS of the breast , *BREAST cancer diagnosis , *MAMMOGRAMS , *BREAST cancer prognosis ,CANCER histopathology - Abstract
Microcalcifications (MCs) are routinely used to detect breast cancer in mammography. Little is known, however, about their materials properties and associated organic matrix, or their correlation to breast cancer prognosis. We combine histopathology, Raman microscopy, and electron microscopy to image MCs within snap-frozen human breast tissue and generate micron-scale resolution correlative maps of crystalline phase, trace metals, particle morphology, and organic matrix chemical signatures within high grade ductal carcinoma in situ (DCIS) and invasive cancer. We reveal the heterogeneity of mineral-matrix pairings, including punctate apatitic particles (<2 µm) with associated trace elements (e.g., F, Na, and unexpectedly Al) distributed within the necrotic cores of DCIS, and both apatite and spheroidal whitlockite particles in invasive cancer within a matrix containing spectroscopic signatures of collagen, non-collagen proteins, cholesterol, carotenoids, and DNA. Among the three DCIS samples, we identify key similarities in MC morphology and distribution, supporting a dystrophic mineralization pathway. This multimodal methodology lays the groundwork for establishing MC heterogeneity in the context of breast cancer biology, and could dramatically improve current prognostic models. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
- Author
-
Ollila, David W., Cirrincione, Constance T., Berry, Donald A., Carey, Lisa A., Sikov, William M., Hudis, Clifford A., Winer, Eric P., and Golshan, Mehra
- Subjects
- *
BREAST cancer treatment , *ADJUVANT treatment of cancer , *HER2 protein , *BREAST biopsy , *BREAST cancer diagnosis , *BREAST tumor treatment , *AXILLA , *BIOPSY , *BREAST cancer , *BREAST tumors , *CELL receptors , *COMBINED modality therapy , *SURGICAL excision , *LYMPH nodes , *LYMPH node surgery , *MASTECTOMY , *METASTASIS , *RESEARCH funding , *TUMOR classification , *DUCTAL carcinoma , *SENTINEL lymph node biopsy , *LOBULAR carcinoma , *THERAPEUTICS - Abstract
Background: Management of the axilla in stage II/III breast cancer undergoing neoadjuvant systemic therapy (NST) is controversial. To understand current patterns of care, we collected axillary data from 2 NST trials: HER2-positive (Cancer and Leukemia Group B [CALGB] 40601) and triple-negative (CALGB 40603).Study Design: Axillary evaluation pre- and post-NST was per the treating surgeon and could include sentinel node biopsy. Post-NST, node-positive patients were recommended to undergo axillary lymph node dissection (ALND). We report pre-NST histopathologic nodal evaluation and post-NST axillary surgical procedures with correlation to clinical and pathologic nodal status.Results: Seven hundred and forty-two patients were treated, 704 had complete nodal data pre-NST and post-NST. Pre-NST, 422 (60%) of 704 patients underwent at least 1 procedure for axillary node evaluation (total of 468 procedures): fine needle aspiration (n = 234; 74% positive), core needle biopsy (n = 138; 72% positive), and sentinel node biopsy (n = 96; 33% positive). Pre-NST, 304 patients were considered node-positive. Post-NST, 304 of 704 patients (43%) underwent sentinel node biopsy; 44 were positive and 259 were negative (29 and 36 patients, respectively, had subsequent ALND). Three hundred and ninety-one (56%) patients went directly to post-NST ALND and 9 (1%) pre-NST node-positive patients had no post-NST axillary procedure. Post-NST, 170 (24%) of the 704 patients had residual axillary disease. Agreement between post-NST clinical and radiologic staging and post-NST histologic staging was strongest for node-negative (81%) and weaker for node-positive (N1 31%, N2 29%), with more than half of the clinically node-positive patients found to be pathologic negative (p < 0.001).Conclusions: Our results suggest there is no widely accepted standard for axillary nodal evaluation pre-NST. Post-NST staging was highly concordant in patients with N0 disease, but poorly so in node-positive disease. Accurate methods are needed to identify post-NST patients without residual axillary disease to potentially spare ALND. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
4. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.
- Author
-
Dashevsky, Brittany, Goldman, Debra, Parsons, Molly, Gönen, Mithat, Corben, Adriana, Jochelson, Maxine, Hudis, Clifford, Morrow, Monica, and Ulaner, Gary
- Subjects
- *
BONE metastasis , *BREAST cancer diagnosis , *POSITRON emission tomography , *COMPUTED tomography , *DUCTAL carcinoma , *RETROSPECTIVE studies , *LOBULAR carcinoma , *DIAGNOSIS , *THERAPEUTICS - Abstract
Purpose: To determine if the histology of a breast malignancy influences the appearance of untreated osseous metastases on FDG PET/CT. Methods: This retrospective study was performed under IRB waiver. Our Hospital Information System was screened for breast cancer patients who presented with osseous metastases, who underwent FDG PET/CT prior to systemic therapy or radiotherapy from 2009 to 2012. Patients with invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), or mixed ductal/lobular (MDL) histology were included. Patients with a history of other malignancies were excluded. PET/CT was evaluated, blinded to histology, to classify osseous metastases on a per-patient basis as sclerotic, lytic, mixed lytic/sclerotic, or occult on CT, and to record SUVmax for osseous metastases on PET. Results: Following screening, 95 patients who met the inclusion criteria (74 IDC, 13 ILC, and 8 MDL) were included. ILC osseous metastases were more commonly sclerotic and demonstrated lower SUVmax than IDC metastases. In all IDC and MDL patients with osseous metastases, at least one was FDG-avid. For ILC, all patients with lytic or mixed osseous metastases demonstrated at least one FDG-avid metastasis; however, in only three of seven patients were sclerotic osseous metastases apparent on FDG PET. Conclusion: The histologic subtype of breast cancer affects the appearance of untreated osseous metastases on FDG PET/CT. In particular, non-FDG-avid sclerotic osseous metastases were more common in patients with ILC than in patients with IDC. Breast cancer histology should be considered when interpreting non-FDG-avid sclerotic osseous lesions on PET/CT, which may be more suspicious for metastases (rather than benign lesions) in patients with ILC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Web based pathology assessment in RTOG 98-04.
- Author
-
Woodward, Wendy A., Sneige, Nour, Winter, Kathryn, Kuerer, Henry Mark, Hudis, Clifford, Rakovitch, Eileen, Smith, Barbara L., Pierce, Lori J., Germano, Isabelle, Pu, Anthony T., Walker, Eleanor M., Grisell, David Lawrence, White, Julia R., and McCormick, Beryl
- Subjects
- *
CLINICAL pathology , *MAMMOGRAMS , *DUCTAL carcinoma , *BREAST cancer diagnosis , *DIAGNOSIS , *COMPUTER network resources - Abstract
Aims Radiation Therapy Oncology Group 98-04 sought to identify women with 'good risk' ductal carcinoma in situ (DCIS) who receive no significant benefit from radiation. Enrolment criteria excluded close or positive margins and grade 3 disease. To ensure reproducibility in identifying good risk pathology, an optional web based teaching tool was developed and a random sampling of 10% of submitted slides were reviewed by a central pathologist. Methods Submitting pathologists were asked to use the web based teaching tool and submit an assessment of the tool along with the pathology specimen form and DCIS H&E stained slide. Per protocol pathology was centrally reviewed for 10% of the cases. Results Of the 55 DCIS cases reviewed, three had close or positive margins and three were assessed to include grade 3 DCIS, therefore 95% of DCIS cases reviewed were correctly graded, and 89% reviewed were pathologically appropriate for enrolment. Regarding the teaching tool, 13% of DCIS cases included forms that indicated the website was used. One of these seven who used the website submitted DCIS of grade 3. Conclusions Central review demonstrates high pathological concordance with enrolment eligibility, particularly with regard to accurate grading. The teaching tool appeared to be underused. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.